Financial analyst consensus price targets for Hoth Therapeutics fluctuate dynamically based on updates from its preclinical and clinical-stage pharmaceutical pipeline targeting dermatological, oncologic, and inflammatory disorders. Because micro-cap clinical-stage biotechnology stocks experience high volatility, twelve-month target projections established by healthcare analysts often suggest substantial percentage upside from current trading baselines, though individual targets vary widely depending on speculative sentiment and the inherent risks of early-stage drug development.